October 23, 2014 4:31 PM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Gregory Glenn, M.D., Senior Vice President, Research and Development at Novavax will present new immunogenicity data from Novavax' RSV F-Protein Nanoparticle vaccine candidate (RSV F vaccine) clinical trials at the 8th Vaccine & ISV Congress to be held October 26-28, 2014 in Philadelphia, PA at the Hilton Philadelphia City Avenue Hotel.The session presentation title, date and time is listed below:Vaccines against Viral PathogensSunday, October 26, 2014, 3:10 to 3:15 p.m. Immunogenicity of the RSV nanoparticle vaccine in humans and the induction of palivizumab competing antibodies: Review of immunogenicity data from 4 recent clinical trials
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.